Stoke Therapeutics (STOK) Equity Ratio (2022 - 2025)
Stoke Therapeutics (STOK) has 4 years of Equity Ratio data on record, last reported at 0.86 in Q3 2025.
- For Q3 2025, Equity Ratio rose 8.07% year-over-year to 0.86; the TTM value through Sep 2025 reached 0.86, up 8.07%, while the annual FY2024 figure was 0.84, 20.69% up from the prior year.
- Equity Ratio reached 0.86 in Q3 2025 per STOK's latest filing, down from 0.87 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.87 in Q2 2025 and bottomed at 0.68 in Q1 2024.
- Average Equity Ratio over 4 years is 0.77, with a median of 0.76 recorded in 2023.
- Peak YoY movement for Equity Ratio: decreased 9.86% in 2024, then rose 25.79% in 2025.
- A 4-year view of Equity Ratio shows it stood at 0.72 in 2022, then decreased by 3.2% to 0.7 in 2023, then increased by 20.69% to 0.84 in 2024, then grew by 1.41% to 0.86 in 2025.
- Per Business Quant database, its latest 3 readings for Equity Ratio were 0.86 in Q3 2025, 0.87 in Q2 2025, and 0.86 in Q1 2025.